Adalimumab (HUMIRA): a review.
N Scheinfeld - Journal of drugs in dermatology: JDD, 2003 - europepmc.org
N Scheinfeld
Journal of drugs in dermatology: JDD, 2003•europepmc.orgAdalimumab (HUMIRA, Abbott Laboratories) is a new fully human TNF-alpha monoclonal
antibody recently approved for the treatment of rheumatoid arthritis and undergoing trials for
use in treating other conditions, including psoriasis and psoriatic arthritis. This article
reviews its mechanisms of action, clinical trial results, and related discussion.
antibody recently approved for the treatment of rheumatoid arthritis and undergoing trials for
use in treating other conditions, including psoriasis and psoriatic arthritis. This article
reviews its mechanisms of action, clinical trial results, and related discussion.
Adalimumab (HUMIRA, Abbott Laboratories) is a new fully human TNF-alpha monoclonal antibody recently approved for the treatment of rheumatoid arthritis and undergoing trials for use in treating other conditions, including psoriasis and psoriatic arthritis. This article reviews its mechanisms of action, clinical trial results, and related discussion.
europepmc.org